Site Map

Home

About Us

• Overview
• Historical Timeline
• Executive Team
• Board of Directors
• Corporate Responsibility
  • Corporate Giving and Grants
    • Grant Guidelines
    • Submit a Grant Request
  • Prescriber Data Privacy
  • Code of Conduct
  • Compliance Reporting
  • Corporate Compliance
• Corporate Values
• Partnering with Onyx
  • Partnerships
• Awards and Recognitions
• Contact Us

Therapies

• Overview
• Nexavar ® for Advanced Kidney Cancer
  • About Kidney Cancer
  • Resources
• Nexavar ® for Unresectable Liver Cancer
  • About Liver Cancer
  • Resources
• Patient Access

Clinical Development

• Overview
• Clinical Pipeline
• Sorafenib
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
• Carfilzomib
  • Expanded Access Program
  • Multiple Myeloma
  • Solid Tumors
• Oprozomib
  • Solid Tumors
• ONX 0914
• Cell Cycle Kinase Inhibitor

Investors

• Investors
• Event Calendar
• Analyst Coverage
• SEC Filings
• Financial Information
• Stock Information
• Annual Report
• Proxy Materials
• Corporate Governance
  • Board of Directors
  • Board Committees
  • Code of Conduct
  • Trading Policy
• Litigation Update
• Information Request

News & Media

• Overview
• Press Releases
  • Current Press Releases
  • Press Releases 2011
  • Press Releases 2010
  • Press Releases 2009
  • Press Releases 2008
  • Press Releases 2007
  • Press Releases 2006
• Online Media Kit

Careers

• Careers
• Job Openings
• Benefits
• How to Apply